Nishant K Mishra։ When Epilepsy Meets Anticoagulation
Nishant K Mishra, Stroke Director at U.S. Department of Veterans Affairs, shared on LinkedIn about a recent article he and his colleagues co-authored, published in JAMA Neurology, adding:
”Pleased to share our new study in JAMA Neurology: ‘Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy.’
In this international real-world study of adults with epilepsy receiving direct oral anticoagulants (DOACs), antiseizure medication choice was associated with meaningful differences in thromboembolic, bleeding, and mortality outcomes.
Notably, compared with lamotrigine/lacosamide, levetiracetam was associated with a higher thromboembolic risk, as were strong enzyme-inducing antiseizure medications.
These findings raise an important and very practical question: When treating epilepsy in a patient who requires anticoagulation, could antiseizure medication selection itself be a modifiable contributor to vascular outcomes?
Congratulations to Kai Michael Schubert, Marian Galovic, and the entire international collaborative team. Grateful to have contributed to this work.”
Title: Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy
Authors: Kai Michael Schubert, Carolina Ferreira-Atuesta, Arunachalam Soma, Johan Zelano, David J Seiffge, Francesco Brigo, Eugen Trinka, Nishant K Mishra, Emilio Russo, Gregory Y H Lip, Gashirai K Mbizvo, Marian Galovic

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series